Literature DB >> 10603070

Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.

S Kasper1, A Hale, J M Azorin, H J Möller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10603070     DOI： 10.1007/pl00014165

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN： 0940-1334            Impact factor:   5.270


× No keyword cloud information.
  5 in total

Review 1.  [Early recognition and intervention for schizophrenia].

Authors:  N Mossaheb; G Wiesegger; G P Amminger; S Kasper; J Tauscher
Journal:  Nervenarzt       Date:  2006-01       Impact factor: 1.214

2.  Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics.

Authors:  Vicente Molina; Carmen Martín; Alejandro Ballesteros; Alba G Seco de Herrera; Juan Antonio Hernández-Tamames
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-12-30       Impact factor: 5.270

3.  Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics.

Authors:  Haiyun Xu; Hong-Ju Yang; Bryan McConomy; Ronald Browning; Xin-Min Li
Journal:  Front Behav Neurosci       Date:  2010-03-18       Impact factor: 3.558

4.  The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment.

Authors:  Siegfried Kasper; Hans-Jürgen Möller; Anthony Hale
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-05-20       Impact factor: 5.270

Review 5.  Sertindole : a review of its use in schizophrenia.

Authors:  David Murdoch; Gillian M Keating
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.